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Previous studies have narrowed the interval containing PSORS1, the psoriasis-susceptibility locus in the major
histocompatibility complex (MHC), to an ∼300-kb region containing HLA-C and at least 10 other genes. In an
effort to identify the PSORS1 gene, we cloned and completely sequenced this region from both chromosomes of
five individuals. Two of the sequenced haplotypes were associated with psoriasis (risk), and the other eight were
clearly unassociated (nonrisk). Comparison of sequence of the two risk haplotypes identified a 298-kb region
of homology, extending from just telomeric of HLA-B to the HCG22 gene, which was flanked by clearly nonho-
mologous regions. Similar haplotypes cloned from unrelated individuals had nearly identical sequence. Combina-
torial analysis of exonic variations in the known genes of the candidate interval revealed that HCG27, PSORS1C3,
OTF3, TCF19, HCR, STG, and HCG22 bore no alleles unique to risk haplotypes among the 10 sequenced
haplotypes. SPR1 and SEEK1 both had messenger RNA alleles specific to risk haplotypes, but only HLA-C and
CDSN yielded protein alleles unique to risk. The risk alleles of HLA-C and CDSN (HLA-Cw6 and CDSN*TTC)
were genotyped in 678 families with early-onset psoriasis; 620 of these families were also typed for 34 mi-
crosatellite markers spanning the PSORS1 interval. Recombinant haplotypes retaining HLA-Cw6 but lacking
CDSN*TTC were significantly associated with psoriasis, whereas recombinants retaining CDSN*TTC but lacking
HLA-Cw6 were not associated, despite good statistical power. By grouping recombinants with similar breakpoints,
the most telomeric quarter of the 298-kb candidate interval could be excluded with high confidence. These results
strongly suggest that HLA-Cw6 is the PSORS1 risk allele that confers susceptibility to early-onset psoriasis.
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Psoriasis is an inflammatory and hyperproliferative skin
disease affecting ∼2% of the United States population.1
The cutaneous manifestations of psoriasis are unpleasant
and obvious, with a negative impact on quality of life.2
Moreover, up to 40% of psoriatics develop psoriatic ar-
thritis; in 5% of psoriatics, the arthritis is severe and
deforming.3 The disease is characterized by marked hy-
perplasia and altered differentiation of the epidermis,
greatly increased blood flow, leukocytic infiltration of
the skin, and a poorly understood relationship with ner-
vous-system function.4 Many observations suggest that
psoriasis is mediated by T cells with a Th1-dominated
cytokine profile.5 However, the root cause of psoriasis
remains unknown.
Twin and family studies clearly demonstrate that pso-
riasis has a genetic basis and is multifactorial in most if
not all cases.6 However, despite numerous genetic link-
age studies yielding at least 19 candidate loci, the iden-
tities of the genes involved remain unclear.7 Nevertheless,
there is general agreement that a major genetic determi-
nant of psoriasis, designated “psoriasis susceptibility 1”
(PSORS1 [MIM 177900]), resides in the major histo-
compatibility complex (MHC).8
The existence of allelic associations between psoriasis
and human leukocyte antigen (HLA) genes in the MHC
has been appreciated for 130 years.9 There are numerous
reports of strong allelic associations with the gene en-
coding HLA class I antigen HLA-Cw6.6 This association
is particularly strong in patients with an early age at on-
set10 and in patients with the guttate subtype of psoria-
sis.11 These findings have led many researchers to suggest
that HLA-Cw6 is the disease allele at PSORS1. This
would be consonant with knowledge that MHC class I
molecules play an important role in the function of CD8
T cells.5 However, proof of this assertion is lacking.
The major obstacle to confirming or refuting the role
of HLA-Cw6 in psoriasis has been linkage disequilib-
rium (LD). The MHC is characterized by extensive and
presumably selection-driven variation, as well as the ex-
istence of particularly strong extended haplotypes.12 Over-
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Table 1
Composition of the Family Sample
NO. OF
AFFECTED
MEMBERS
NO. OF NUCLEAR
FAMILIESa
NO. OF
MULTIGENERATIONAL
FAMILIES BY NO.
OF GENERATIONS
TOTAL
NO. OF
FAMILIESDyads Triads Sibships 3 4 5 6
1 57 218 7 1 0 0 0 283
2 13 79 107 20 0 0 0 219
3 0 4 55 34 4 0 0 97
4 0 0 14 22 2 0 0 38
5 0 0 1 12 5 0 0 18
6 0 0 0 7 14 1 1 23
Total 70 301 184 96 25 1 1 678
a Nuclear (2-generation) families are classified as dyads, triads, or sibships (af-
fected child and one or more collected siblings, with or without parents).
all, the recombination rate for the MHC is lower than
the genomewide rate determined by sperm typing, and,
in addition, the MHC includes defined subregions of low
recombination.12 One of these regions, characterized by
a 2.3-fold reduction in recombination rate relative to the
genomic average, resides just telomeric to HLA-C.12 At
least 10 genes have been identified within this region.13
As the allelic variation in these genes has been charac-
terized and tested, it has become clear that many of these
genes are also strongly associated with psoriasis. At-
tempts to stratify associations according to HLA-C
status have usually failed to identify any association in-
dependent of HLA-Cw6. Against this background, it has
become evident that neither the magnitude nor the sta-
tistical significance of individual allelic associations can
provide definitive insight into the identity of the PSORS1
gene.
To overcome this challenge, we and others have turned
to recombinant ancestral haplotype analysis. By accumu-
lating and analyzing sufficient numbers of subjects, it is
possible to identify individuals carrying only portions of
the ancestral PSORS1 risk haplotype and to assess the
risk conferred by those haplotypes. Our laboratory used
STRs for this purpose,14 and Veal et al. used SNPs.15
Both studies confirmed that present-day MHC haplo-
types have been generated by recombination events in-
volving extended ancestral haplotypes.16 Together with
more recent work,17 both efforts have identified a region
of ∼300 kb just telomeric of HLA-B as the interval con-
taining PSORS1.
In the present study, we extended our earlier haplotype
analysis14 to include 16 polymorphisms in the HLA-C
and CDSN genes and 188 additional pedigrees. We also
incorporated improved methods for haplotype recon-
struction. Finally, we used cloning and shotgun DNA
sequencing to determine the complete genomic DNA se-
quence of the 300-kb PSORS1-risk region for 10 haplo-
types falling into seven distinct haplotype clusters. Two
of these are associated with psoriasis (risk), and the other
five are unassociated (nonrisk). Comparison of sequence
for the two risk haplotypes confirmed the existence of
a 298-kb region of homology flanked by two clearly
nonhomologous regions. Sequences of haplotypes drawn
from the same cluster were nearly identical. Comparison
of risk and nonrisk haplotypes revealed that only two
genes (HLA-C and CDSN) in the 298-kb candidate in-
terval encode variants unique to risk at the level of trans-
lated protein. Focusing on those haplotypes that have
undergone recombination events between the risk alleles
of HLA-C and CDSN, we further report that only those
bearing HLA-Cw6 confer risk of psoriasis and that we
can exclude the telomeric 25% of the risk interval with
high confidence. Although the possibility of regulatory
variants or unknown genes in the remainder of this in-
terval cannot be completely excluded, this combined se-
quencing and haplotype-mapping approach strongly sup-
ports HLA-Cw6 as the major PSORS1 disease allele in
early-onset psoriasis.
Subjects and Methods
Family Sample
The study sample consisted of 678 pedigrees of various struc-
tures (table 1), which either were identified through the derma-
tology services of the University of Michigan Medical Center,
the Ann Arbor Veterans Affairs Hospital, the University of
Kiel, and Henry Ford Hospital or were provided by the Na-
tional Psoriasis Foundation Tissue Bank. Only families in which
the proband’s age at onset was !40 years were included.10
Individuals were considered to be affected if chronic plaque or
guttate psoriasis lesions covered 11% of the total body surface
area or if at least two skin, scalp, nail, or joint lesions were
clinically diagnostic of psoriasis.18 A total of 2,723 individuals
were recruited, 1,432 of whom were affected with psoriasis.
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Table 2
Nomenclature, Amplification Primers, and Genomic
Locations of Microsatellite and Indel Markers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 3
Nomenclature, Amplification Primers, Probes, and
Genomic Locations of SNPs Used in the Present
Study
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Most (642) of the pedigrees were of white European ancestry.
Informed consent was obtained from all subjects, under pro-
tocols approved by the institutional review boards of the par-
ticipating institutions.
Markers and Genotyping
The 34 microsatellite markers originally used for haplotype-
clustering analysis of a 490-pedigree subset of the current sam-
ple14 were genotyped for an additional 130 pedigrees. HLA-
C and HLA-B antigen alleles were genotyped for 157 of the
combined sample of 620 pedigrees, with use of DNA-based
methods for HLA-C and serological methods for HLA-B, as
described elsewhere.19 Seven SNPs in HLA-C and an additional
eight SNPs and one indel in CDSN were genotyped for all 678
families in the current analysis (i.e., the 620 families subjected
to microsatellite typing plus an additional 58 families). To lo-
cate ancestral recombination breakpoints between HLA-C and
CDSN, 15 additional markers (12 SNPs and 3 indels) were
genotyped for all individuals carrying either of two rare hap-
lotypes that are possibly associated with psoriasis (HLA-Cw6-
B45 and HLA-Cw7-B58). Nomenclature, amplification prim-
ers, probes, and genomic locations for all markers used in this
study are listed in tables 2 and 3.
The SNPs typed for HLA-C (SNP25, SNP38, SNP39,
SNP26, SNP36, SNP40, and SNP37) (table 3) are located in
exons 2 and 3 of the gene at positions 213, 218, 341, 361,
387, 459, and 540 of GenBank mRNA reference sequence
NM_002117.4 (unless otherwise noted, mRNA numberings
denote the A of the initiator codon as nt1). When haplotype
phase could be unambiguously determined, the two SNPs at
positions 213 and 361 allowed HLA-C to be typed to a biallelic
level by distinguishing all HLA-Cw6 alleles (HLA-Cw0602–
Cw0613) from the other 186 known alleles of the gene (July
2005 release 2.10.0 of the IMGT/HLA Sequence Database
maintained by the HLA Informatics Group20 [see the Anthony
Nolan Trust Web site]). Typing all seven SNPs provided ab-
solute discrimination of HLA-Cw6 alleles, even when phase
could not be determined with certainty, and allowed classifi-
cation of HLA-C types into 15 allele groups when phasing
was unambiguous. The nine polymorphisms typed for CDSN
(SNP1, SNP34, SNP2, SNP9, SNP3, SNP35, SNP4, SNP5, and
SNP6) (table 3) are all protein-altering variations and are lo-
cated at positions 52, 166, 428, 447–449, 605, 1201, 1222,
1229, and 1579 of GenBank mRNA reference sequence
NM_001264.2. Seven of these polymorphisms constitute the
five different combinations that make the psoriasis-associated
risk haplotypes unique among the 10 sequenced haplotypes
of this study, and the other two (SNP34 and SNP35) define
two known CDSN protein variants among psoriasis-risk hap-
lotypes (see the “Results” section for more details).
DNA was prepared from peripheral-blood mononuclear cells
or Epstein-Barr virus–immortalized lymphoblastoid cell lines,
as described elsewhere.21 Microsatellite markers were genotyped
either by 32P-labeled primers and polyacrylamide gel electro-
phoresis, as described elsewhere,21 or by fluorescent labeling
followed by capillary electrophoresis on ABI Prism 3100 Ge-
netic Analyzers (Applied Biosystems). Indels were typed by the
same method. SNPs were typed by single-base primer exten-
sion, as implemented in the SnapShot assay protocol (Applied
Biosystems), per the manufacturer’s instructions. Genotypes
were checked for Mendelian inheritance errors by use of Ped-
stats22 and Pedmanager and, for unlikely genotypes, by use of
the “error” option of version 1.0-alpha of Merlin.23
Genomic DNA Cloning and Sequencing
High–molecular weight DNA was isolated by sucrose den-
sity gradient centrifugation, and large-insert (∼35–45 kb) li-
braries were prepared in either a SuperCos1 cosmid vector
(Stratagene) or a pEPIFOS-5 fosmid vector (Epicentre Bio-
technologies), per the manufacturers’ instructions. Each library
had at least 12-fold haploid genome coverage. Libraries were
screened using gel-purified probes derived by PCR amplifica-
tion from the region of interest, and the probes were labeled
with 32P by random priming. To map clones, we sequenced
clone termini and used microsatellite and SNP genotyping to
determine whether each clone was derived from the maternally
or paternally inherited chromosome. Overlapping clones were
selected for sequencing, to provide complete coverage of a 350-
kb target region on both chromosomes.
For sequencing, the large insert fosmid or cosmid clones were
sheared into ∼1-kb fragments by use of a nebulizer (Invitro-
gen), were gel purified, were blunt ended, were cloned into a
pGEM3-ZF() plasmid vector (Promega), and were sequenced
in both directions with the vector primers SP6 and T7. Raw
sequences were assembled into contigs by use of SeqMan
(DNAStar, version 6.0), assisted by alignment of shotgun se-
quence against an HLA-Cw7-B8 reference sequence from the
COX homozygous cell line.24 The coordinate system used in
the tables and figures of the present study was based on this
reference sequence, starting with the first base of the 5′ primer
(GCAACTTTTCTGTCAATCCA) used to amplify microsat-
ellite marker D6S273 and extending in the telomeric direction
(see table 4 for a listing of accession numbers for the reference
sequence). High-quality sequence coverage from at least two
different plasmid subclones—and from both strands, whenever
possible—was required for the entire cosmid or fosmid insert.
Examination of overlapping regions of sequenced clones for
the same haplotype of the same individual yielded an estimated
total error rate of well under one error per 100,000 bases,
which is consistent with the error rate seen for the Human
Genome Project.25
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Table 4
GenBank Accession Numbers and HLA-C and HLA-B Alleles for Haplotype Sequences
Haplotype Clustera
and Sourceb HLA-Cc HLA-Bc GenBank Accession Number(s)
7 (66):
Patient 144 120301 3801 DQ249175
Patient 495 120301 3801 DQ249179
37 (14):
Patient 541 07020103 070201 DQ249181
PGF cell line 07020103 070201 AL671883, AL662850, AL662844, and AL669830
41 (19):
Patient 541 0602 5001 DQ249182
44 (25):
Patient 495 0602 570101 DQ249180
Patient 388 0602 570101 DQ249178
DBB cell line 0602 5701 CR759814, CR38829, CR753819, CR847993, and CR753812
49 (26):
Patient 135 070101 080101 DQ249172
Patient 144 070101 080101 DQ249174
COX cell line 070101 080101 AL670886, AL662847, AL662866, AL669854, AL845556, AL662833, AL662867, and AL663093
51 (17):
Patient 135 0802 140201 (B65) DQ249173
Patient 218 0802 140201 (B65) DQ249176
60 (48):
Patient 218 030401 15010101 (B62) DQ249177
MCF cell line 030401 15010101 (B62) CR759828, CR933862, CR759815, CR938714, CR936880, CR759805, and CR759772
a Haplotype-cluster number for the new analysis of the present study (cluster number from our original study14).
b Patient numbers refer to haplotypes sequenced for the present study; cell lines refer to HLA-homozygous cell lines sequenced by the Sanger Institute for
the MHC Haplotype Project.
c HLA-C and HLA-B allele designations follow the nomenclature of the IMGT/HLA Sequence Database, release 2.10.0, maintained by the HLA Informatics
Group.20 HLA-B alleles in parentheses are serological equivalents that are used elsewhere in this study in preference to the DNA allele designations listed here.
Comparison of Sequenced Haplotypes
Overlapping cosmid and fosmid clone sequences were assem-
bled into a single contig for each of the 10 haplotypes (Gen-
Bank accession numbers are provided in table 4). Haplotype
contigs were then aligned with each other in SeqMan. When-
ever necessary, sequence alignments were manually adjusted
to yield the minimum possible number of polymorphisms. For
each polymorphism, its location in the COX HLA-Cw7-B8
reference sequence and its alleles for the 10 haplotypes were
recorded. Haplotype contig sequences were then compared
with that of the HLA-Cw6-B57 contig by determining a
weighted percentage difference of polymorphic alleles over 2.5-
kb intervals. Weighting each polymorphism by the inverse of
the number of variations found within 1.25 kb of the poly-
morphism allowed the percentage-difference metric to incor-
porate a true local density of polymorphisms.
Analysis of Candidate Genes
All expressed and transcript genes within the 300-kb PSORS1
interval that are listed in a recently published gene map for
the human MHC13 were selected as candidates for PSORS1
(table 5). With the exception of a computer-predicted locus
(LOC442199), the information in this table corresponds to
all genes shown in build 35.1 of National Center for Biotech-
nology Information (NCBI) Map Viewer for the candidate in-
terval. For each gene, all mRNA sequences available in build
186 of NCBI Unigene were considered. Two-sequence BLAST
was used to align each mRNA sequence with the relevant por-
tion of the COX HLA-Cw7-B8 genomic reference sequence,
and all exon boundaries were mapped. The mRNA sequences
for each gene were then sorted into groups with similar splicing
patterns. When more than one sequence existed for a given
splice variant, that sequence with the most-complete 5′ and 3′
UTRs was used as a reference (reference mRNAs are provided
in table 5). All variations among the 10 sequenced haplotypes
that occurred in the spliced transcript of the reference mRNA
sequence were located, and their effect on the predicted protein
sequence was determined. The predicted coding sequence in-
cluded as an annotation within the GenBank sequence record
was used whenever available; the longest ORF predicted by
MacVector (version 6.5.3 [Accelrys]) was used instead for
those two reference mRNA sequences without this information
(BX647174.1 for TCF19 and AK094433.1 for HCG22). Ver-
sion 0.97-600-1000 of the MINCOV program (Stanford Cen-
ter for Tuberculosis Research Web site)26 was used to search
for minimal sets of polymorphism alleles that distinguished the
two risk haplotypes (Cw6-B57 and Cw6-B50) from the eight
nonrisk haplotypes. Each splice variant of each gene was ana-
lyzed; separate analyses were conducted for all polymorphisms
within the mRNA transcript, as well as for the subset of pro-
tein-altering mutations within the coding sequence.
Haplotype Reconstruction
Haplotypes were reconstructed by three different methods.
The first method generated maximum-likelihood haplotypes
with Merlin,23 with a new version that models LD among clus-
ters of tightly linked markers.27 Population-haplotype fre-
quencies within the cluster were computed by Merlin from
our pedigree data with an expectation-maximization algo-
rithm. The second method used a combination of Merlin and
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Table 5
Nomenclature and mRNA Reference Sequences for All Known Genes in the PSORS1 Candidate Interval
Gene Symbola
HGNC
Symbolb HGNC IDc Entrez IDd HGNC Namee mRNA Reference Sequence(s)f
HLA-C HLA-C 4933 3107 Major histocompatibility complex, class I, C NM_002117.4
HCG27 HCG27 27366 253018 HLA complex group 27 NM_181717.1 and BC041465.2
PSORS1C3 PSORS1C3 17203 170681 Psoriasis susceptibility 1 candidate 3 AY484516.1
OTF3 POU5F1 9221 5460 POU domain, class 5, transcription factor 1 NM_002701.3 and NM_203289.2
TCF19 TCF19 11629 6941 Transcription factor 19 (SC1) S53374.1, BC033086.1, BC044632.1, and BX647174.1
HCR CCHCR1 13930 54535 Coiled-coil alpha-helical protein 1 NM_019052.2, AB112474.1, AB029331.1, and AK000533.1
SPR1 PSORS1C2 17199 170680 Psoriasis susceptibility 1 candidate 2 NM_014069.1
SEEK1 PSORS1C1 17202 170679 Psoriasis susceptibility 1 candidate 1 NM_014068.1 and AF484419.1
CDSN CDSN 1802 1041 Corneodesmosin NM_001264.2
STG C6orf15 13927 29113 Chromosome 6 open reading frame 15 AY358438.1
HCG22 HCG22 27780 285834 HLA complex group 22 AK094433.1
a Gene symbol used in the present study.
b Official gene symbol that has been approved by the HUGO Gene Nomenclature Committee (HGNC).
c A unique gene ID provided by the HGNC.
d Gene ID in the Entrez Gene database curated by the NCBI.
e Official gene name that has been approved by the HGNC.
f GenBank entry number(s) for mRNA sequences used as references in the present study. Multiple mRNA sequences for a gene correspond to multiple known
splicing variants.
PHASE,28,29 as described in detail elsewhere.30 In brief, max-
imum-likelihood haplotypes were created with an implicit as-
sumption of linkage equilibrium between markers by use of
the “best” option of Merlin (version 0.10.2). Phase ambiguities
in the most-likely Merlin haplotypes were then resolved by
PHASE (version 2.1.1) whenever the confidence of the phase
call was at least 99%. The third method used version 1.5.5
of the family-based association test (FBAT)31,32 (see the Har-
vard School of Public Health Web site), which reconstructs
haplotypes in a probabilistic manner, with a conditioning ap-
proach that allows use of haplotypes with missing genotype
or phase information without introducing bias.33
Haplotypes for the nine genotyped polymorphisms of CDSN
and the seven typed SNPs of HLA-C were reconstructed by
method 1. Haplotypes for HLA-C and CDSN in the 58 families
typed only for these two genes were also generated by method
1; the entire pedigree sample was used to improve estimation
of haplotype frequencies in the underlying population. Thirty-
six marker haplotypes (HLA-Cw6, CDSN, and 34 microsa-
tellites) in 620 families were generated by method 2 because
of computational constraints of methods 1 and 3.
Accuracy of HLA-C and CDSN typing was confirmed by
several methods. For CDSN, identical haplotypes were obtained
with methods 1 and 2, and the founder-haplotype frequencies
produced by method 3 were very similar to those yielded by
the first two methods. Accuracy of haplotypes for the seven
typed SNPs of HLA-C generated by method 1 was assessed
by comparison of the inferred haplotype configuration for each
person with the predicted configurations for all pairwise com-
binations of the 198 known HLA-C alleles. Haplotypes were
retained if they were the only possible outcome given the ge-
notypes of that person and other family members or if the only
other choices involved HLA-C haplotypes known to be very
rare in the study population. Moreover, method 3 frequencies
for 7-SNP HLA-C haplotypes were very similar to those of
method 1. As mentioned before, HLA-C haplotypes could be
absolutely discriminated to the level of HLA-Cw6 versus non–
HLA-Cw6 in the absence of external phase information from
the population or other family members.
Accuracy of HLA-C–CDSN haplotypes was assessed by com-
parison of the results of methods 1 and 3, which yielded very
similar haplotype frequencies. Merlin, as used by method 2
for 36-marker haplotype construction, incorrectly assumes link-
age equilibrium among markers, so the reliability of the most-
likely haplotype vectors of Merlin was assessed by comparison
of them with all possible haplotype vectors (under the assump-
tion of no recombination) for each member of the pedigree
sample. Only 0.006% (5 of 88,340) of the alleles were phased
differently between the two sets. For 1,584 alleles, phase was
ambiguous in one or more of the possible haplotypes for a
person but resolved in the most likely haplotype; when method
2 was applied to that set of possible haplotypes for each ped-
igree with the most such discrepancies, all but 51 of these
ambiguous phases were resolved identically for the possible
and most likely haplotype.
For all haplotypes in this study, inferred haplotypes of un-
collected family members were discarded for purposes of anal-
ysis, because their use by the transmission/disequilibrium test
(TDT) and pedigree disequilibrium test (PDT) can lead to
bias.34,35 Because these two tests can handle only one possible
haplotype configuration per individual, haplotypes with am-
biguous or missing phase information were also discarded,
even though use of only phase-known haplotypes can also lead
to bias.36 Bias of this sort should be minimal—none of the
CDSN haplotypes and only 0.7% of the multiallelic HLA-C,
0.2% of the biallelic HLA-C, and 0.3% of 36-marker haplo-
types needed to be discarded because of missing or unresolved
phase information for those people with genotypes for at least
one marker of the haplotype.
Haplotype Clustering
For founder chromosomes of the pedigree sample, 36-marker
haplotypes were clustered using an average-distance agglom-
erative hierarchical method with a percentage-difference met-
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Table 6
Number of Families Informative for Association Testing
GENE OR HAPLOTYPE
NO. OF
INFORMATIVE
FAMILIES
NO. OF
TYPED
FAMILIESTDT PDT FBATa
HLA-C (biallelic) 492 530 544 677
HLA-C (multiallelic) 623 634 642 670
CDSN 629 640 649 678
HLA-C (biallelic) and
CDSN haplotypes 625 636 648 677
36-Marker haplotypes 576 584 … 620
NOTE.—Although typing success was uniformly high (199%) for all
markers and haplotypes of the present study, the number of infor-
mative families varies because some families were not typed for the
34 microsatellite markers, the three association tests differ in what
sort of pedigrees they can use, and dyads cannot be tested for biallelic
markers. The numbers shown for each association test count only those
families with at least one typed and phenotypically informative unit.
For the TDT, this unit is a triad or dyad; for the PDT, it is a triad,
dyad, or discordant sib pair (an affected child and unaffected sibling);
and, for the FBAT with the settings used, it is a triad, dyad, discordant
sib pair, or a sibship with three or more affected siblings.
a As indicated by the ellipses (…), the FBAT cannot be applied to
the 36-marker haplotypes, because the computational demands are
too great; furthermore, FBAT can test only groups of haplotypes with
exact matches for all alleles, and these constitute only a small fraction
of all haplotypes in the sample.
ric. To qualify for clustering, at least half of the alleles of the
haplotype were required to be typed and of known phase. A
total of 2,710 founder haplotypes either were directly typed
or were potentially inferable from other typed members of the
pedigrees; of these, 2,700 qualified for clustering. Untyped or
unphased alleles—which comprised 0.10% and 0.14%, re-
spectively, of the alleles of clustered founder haplotypes—were
labeled as “missing” rather than as “zero,” to avoid false
matches and mismatches. The criteria for assignment of hap-
lotypes to a cluster were 80% homogeneity of marker alleles
and a minimum of five founders. All other haplotypes were
lumped together into a single cluster. Clusters were then num-
bered and assigned to all nonfounders in the pedigrees, ac-
cording to the segregation of founder chromosomes. Recom-
binations between founder haplotypes occurred six times among
∼1,400 informative meioses in the pedigree sample; the re-
sulting recombinant haplotypes were discarded for all individ-
uals inheriting them. Genotypes for HLA-C and HLA-B an-
tigen alleles, which were available for only a subset of the
pedigree sample, were assigned to haplotype clusters by in-
spection of informative pedigrees.
Mapping Breakpoints of Recombinant Haplotypes
Breakpoints for haplotypes with an ancestral recombination
between the psoriasis-risk alleles of CDSN and HLA-C were
mapped using the 34 microsatellite markers. Identity with the
risk alleles of the PSORS1 candidate region was assessed, al-
lowing for mutable markers for which two or three alleles
(differing in size by one or two tandem repeats) occur on risk
haplotypes that are otherwise similar. Of the 58 pedigrees that
were typed only for CDSN and HLA-C, 2 carried a recom-
binant haplotype; all members of these two families were typed
for additional markers, to map the breakpoints to the same
resolution as the other recombinant haplotypes. Because asso-
ciation testing was used to exclude portions of the PSORS1
candidate region, breakpoints of HLA-Cw6/CDSN*TTC re-
combinants (which were found to be unassociated with pso-
riasis) were mapped to the last marker on both sides of CDSN
that bears a risk allele, to ensure that these haplotypes fully
retained the portion of the candidate interval being tested
for exclusion. Conversely, breakpoints of HLA-Cw6/CDSN*
TTC recombinants (which were found to be positively as-
sociated with psoriasis) were mapped to the first marker on
both sides of HLA-C that does not carry a risk allele, to ensure
that these haplotypes had not retained any portion of the
PSORS1-risk interval being tested for exclusion. To better
compare two rare putative risk haplotypes (HLA-Cw7-B58
and HLA-Cw6-B45) with the reduced PSORS1-candidate
region, 15 additional markers (M6S235–M6S237, SNP66–
SNP72, and SNP74–SNP78) were used to fine map their
breakpoints. These breakpoints were mapped to the first mark-
ers with a nonrisk allele, to delineate the largest possible por-
tions of these haplotypes that are homologous to the ancestral
HLA-Cw6-B57 risk haplotype.
Family-Based Association Tests
Pedigrees were analyzed for putative disease-associated al-
leles and haplotypes with three different family-based associ-
ation tests: the TDT,37 the PDT,38,39 and the FBAT.31,32 All three
methods were implemented as biallelic two-sided tests of the
null hypothesis of no association in the presence of linkage.
Both the TDT and PDT were extended to include dyads (af-
fected child and one collected parent) when triads (affected
child and two collected parents) were not available, with ap-
propriate precautions.40 For the TDT, a single triad or dyad
was randomly extracted from each pedigree. Because results
vary depending on the particular random selection, the analysis
was repeated 999 times with different random number seeds,
and the median result was reported. Exact binomial P values
were used. For the PDT, we used the PDT-avg test, which gives
equal weighting to all families. All triads, dyads, and discor-
dant sib pairs in a family contributed to the test. We also com-
puted , a standardized measure of association between the
—
D
disease and marker loci, as assessed by the PDT, which has a
range of 1 to 1.17 For the FBAT, version 1.5.5 of the soft-
ware41 was used with an additive model, the empirical vari-
ance, and an offset of 0. FBAT does not output a measure of
LD that is independent of sample size; for this purpose, we
calculated a statistic S*, which is the mean deviation of the
FBAT test statistic S from its expected value over all families
that are genotypically informative for the test allele. The num-
ber of families informative for association testing varied, de-
pending on both the locus and test (table 6).
The equality of TDT percentage transmission (%T) values
for two risk alleles of the same locus or haplotype was tested
by generating 100,000 simulated data sets. In each simulation,
gentoypes were randomly assigned to the parents on the basis
of observed allele frequencies in founders and an assumption
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Figure 1 Delineation of the PSORS1 candidate interval. Known genes are shown below the coordinate axis, and key microsatellite markers
are shown above. The candidate interval is depicted as originally defined (59.7-kb RH1 interval14), after its initial expansion on the basis of
sequencing the regions immediately flanking RH1 (140-kb PSORS1 interval) and after incorporating results with reassessment of the association
of an HLA-Cw8-B65 haplotype with psoriasis (300-kb PSORS1 interval17).
of Hardy-Weinberg equilibrium. The probability of segregation
from parents carrying exactly one risk allele was based on the
observed %T for all risk alleles combined; for homozygous par-
ents, alleles were assumed to segregate in a Mendelian fashion.
Significance levels were determined by comparison of the dif-
ference of %T values in our original pedigree sample with the
difference of %T values in simulated pedigrees.
Recombinant haplotypes separating the risk alleles of HLA-
C and CDSN were tested for their association with psoriasis.
Correction for multiple correlated tests was determined using
a Monte Carlo method.42 In brief, founder haplotypes were
randomly assigned on the basis of observed allele frequencies
and an assumption of Hardy-Weinberg equilibrium, and Men-
delian segregation of founder haplotypes to nonfounders was
then simulated. Association tests were repeated in the simu-
lated data, and the most significant P value among all associ-
ation tests was stored for each of 100,000 simulated samples,
to create a reference distribution. The corrected P value for
each test of the actual data was then simply the rank of its
nominal P value within the sorted reference distribution.
TDT Power Analysis
Power to detect association with various recombinant hap-
lotypes was determined by simulation, under the alternative
hypothesis of LD between psoriasis and the marker locus. We
generated 100,000 samples of triads and dyads that were
equivalent in size and parental haplotype-cluster frequencies
to those extracted from the observed pedigrees for the TDT,
using a gene-drop algorithm with rejection sampling.30 We as-
sumed a population prevalence of 2% for psoriasis. Estimates
of genotype relative risk (GRR) for carriers of a recombinant
haplotype presumed to contain PSORS1 were based on esti-
mates of GRR for HLA-Cw6—10.4 for homozygotes and 5.2
for heterozygotes.17 Because only a small fraction of haplotypes
carrying HLA-Cw6 exhibit an ancestral recombination be-
tween it and the CDSN risk allele, the GRR values for the
relatively rare recombinants between these two alleles must be
adjusted accordingly. The penetrance of noncarriers of recom-
binant haplotypes will be nearly double that of non–HLA-
Cw6 carriers, so GRR values need to be halved to ∼5 for ho-
mozygotes and ∼3 for heterozygotes. Nominal power was then
estimated using a type I error rate of 0.05 for each individual
test. Estimates of corrected power utilized a type I error of
0.016, which was determined by simulation (see above) to
ensure a global type I error rate of 0.05 for all 10 tests of
recombinant haplotypes.
Results
Delineation of the PSORS1 Interval
Our original localization study analyzed association
between psoriasis and 62 microsatellite markers situ-
ated throughout the MHC.14 The strongest associations
were found for markers lying within a 1.2-Mb region
of the central MHC. A comparison of clusters of 34-
marker haplotypes spanning this region narrowed the
candidate interval for PSORS1 to a 59.4-kb region des-
ignated “RH1” (fig. 1), which was the shortest micro-
satellite haplotype segment common to all identifiable
risk haplotypes.14 RH1 was therefore our original target
for DNA sequencing. However, analysis of sequences
flanking RH1 and evidence that an uncommon haplo-
type showing association with psoriasis in our original
sample is probably not associated17 prompted us to ex-
tend the PSORS1 interval to 300 kb, bounded centrom-
erically by HLA-B and telomerically by M6S224 (fig.
1).
Sequencing Strategy
Rather than sequence genomic DNA directly, we chose
to clone the region first. In this way, we could separate
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Table 7
Homogeneity of Consensus Alleles for the
Sequenced Haplotype Clusters
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
maternal and paternal chromosomes, avoid the difficulty
of specifically amplifying regions with genomic repeats,
and still sequence haplotypes originating in affected in-
dividuals from our sample. We selected five individuals
for sequencing, which yielded a total of 10 haplotypes
from seven of the distinct haplotype clusters of our orig-
inal study.14 Two of these haplotype clusters were asso-
ciated with psoriasis, and the other five were unasso-
ciated. Among risk haplotypes, HLA-Cw6-B57 was se-
lected because it was the most common in our sample,
and HLA-Cw6-B50 was chosen because our earlier stud-
ies showed that it limited the candidate interval on its
telomeric end. The chosen nonrisk haplotypes (Cw12-
B38, Cw7-B7, Cw7-B8, Cw8-B65, and Cw3-B62) rep-
resent five of the eight most common nonrisk-haplotype
clusters in our original study.14 The Cw8-B65 cluster was
originally selected as a risk haplotype, but subsequent
analysis17 led us to reassign it to the nonrisk category.
We deliberately selected three haplotypes (Cw12-B38,
Cw7-B8, and Cw8-B65) to be cloned and sequenced
twice, to gain a better understanding of the similarity of
haplotypes belonging to the same cluster that were
cloned from unrelated individuals. The seven distinct
haplotypes selected for sequencing were carried by 34%
of the founder chromosomes in our original study.14
Homogeneity of Haplotypes from the Same Cluster
Our original study used a threshold of 80% identity
among marker alleles to define clusters for 34-marker
haplotypes spanning the PSORS1 candidate interval.14
If the clustered sequences are not much more similar
than this for all polymorphisms in the interval, then
sequencing one member as a representative of the entire
cluster would be of little value. Therefore, as a prelude
to DNA sequencing, we assessed the homogeneity of the
haplotype clusters to be sequenced by determining the
percentage of founder haplotypes in each cluster that
carry the consensus allele for the marker. This analysis,
shown in table 7, revealed that the mean homogeneity
of the seven sequenced haplotype clusters has a range
of 91%–95% (grand mean 93%) when averaged over
all 34 markers, far in excess of the 80% threshold used
to define clusters. Homogeneity was even greater for
the 24 markers within the 362-kb sequenced region and
when the least stable markers (M6S167, M6S168, and
M6S224) were omitted.
Clusters appeared to be even more homogeneous when
SNP and indel variants were considered. Specifically, we
compared our own three duplicate haplotype sequences,
as well as four haplotypes derived from homozygous
MHC typing cell lines sequenced by the Sanger Institute
for the MHC Haplotype Project. With these sequences,
we were able to make eight pairwise comparisons across
the PSORS1-candidate interval, comprising six of the
seven sequenced haplotype clusters. These comparisons
revealed 99.996%–99.999% sequence similarity for hap-
lotypes assigned to the same cluster (table 8). When ex-
pressed as a percentage of divergent alleles for those poly-
morphisms identified among the 10 sequenced haplo-
types, these differences had a range of 0.047%–0.17%.
These data demonstrate that haplotypes assigned to the
same cluster by our methods are indeed nearly identical.
Sequence Characterization of the PSORS1 Interval
Figure 2 depicts the sequence divergence of one exam-
ple of each of the sequenced haplotypes relative to the
HLA-Cw6-B57 haplotype. Note that the divergence be-
tween the two risk haplotypes is very low across an
interval extending from just telomeric of HLA-B (359.8
kb) to just telomeric of the HCG22 gene (657.6 kb). As
defined by the first points at which the two risk-hap-
lotype sequences diverge by 120% over a span of 2.5
kb, the PSORS1-risk interval is 297.8 kb in length. The
two risk haplotypes diverge at 0%–17% (mean 2%;
median 0%) of polymorphic sites within the 298-kb re-
gion of homology, at 39%–82% (median 43%) of sites
in the 35 kb of sequenced centromeric flanking region,
and at 29%–100% (median 75%) of sites in the se-
quenced 25 kb of telomeric flanking region. Thus, se-
quence comparison of the two risk haplotypes allowed
us to more accurately define the risk interval than when
the boundaries were defined using microsatellite mark-
ers14 or SNPs15 and to conclusively demonstrate contin-
uous homology between risk haplotypes throughout the
interval.
Comparison of Risk and Nonrisk Haplotypes
In contrast to the extended region of sequence simi-
larity between the two risk haplotypes, comparisons of
nonrisk haplotypes with the HLA-Cw6-B57 risk hap-
lotype demonstrate extensive variation. However, some
portions of the nonrisk haplotypes HLA-Cw7-B8, HLA-
Cw8-B65, and HLA-Cw12-B38 manifest marked sim-
ilarity to risk haplotypes, with shorter regions of lesser
similarity on nonrisk haplotypes HLA-Cw7-B7 and
HLA-Cw3-B62 (fig. 2).
The bottom panel of figure 2 depicts the total number
of polymorphisms observed among the 10 haplotypes,
per 2.5-kb intervals. This panel reveals a highly uneven
distribution of sequence variation, ranging from a low of
2.4 polymorphisms per kb in the telomeric portion of the
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Table 8
Sequence Comparison of Haplotypes That Belong to the Same Cluster
Clustera, HLA-CB Haplotype, and Pairwise
Haplotype Comparison
Shared
Sequence
Length
(bp)
No. of
Differences
Fraction of
Divergent
Sequences
No. of Known
Polymorphismsb
Fraction of
Divergent
Polymorphisms
7 (66):
Cw12-B38:
Patient 144 vs. patient 495 327,895 11 1/29,809 6,639 1/604
37 (14):
Cw7-B7:
Sanger PGF cell line vs. patient 541 341,361 3 1/113,787 6,415 1/2,138
44 (25):
Cw6-B57:
Sanger DBB cell line vs. patients 495 and 388 313,596 5 1/62,719 5,681 1/1,136
Sanger COX cell line vs. patient 135 342,745 3 1/114,248 6,235 1/2,078
49 (26):
Cw7-B8:
Sanger COX cell line vs. patient 144 338,544 4 1/84,636 6,684 1/1,671
Patient 135 vs. patient 144 319,157 6 1/53,193 6,135 1/1,023
51 (17):
Cw8-B65:
Patient 135 vs. patient 218 336,786 10 1/33,679 6,247 1/625
60 (48):
Cw3-B62:
Sanger MCF cell line vs. patient 218 323,140 6 1/53,857 6,078 1/1,013
a Haplotype-cluster number for the new analysis of the present study (cluster number from our original study14).
b Results are based on polymorphisms observed among the 10 sequenced haplotypes of the present study.
PSORS1 interval to a peak of nearly 80 polymorphisms
per kb in the interval between HLA-B and HLA-C. The
6,856 variations observed within the 362-kb sequenced
interval include SNPs (85.0%), indels (8.5%), SNPs
within indels (4.8%), poly A/T tracts (1.3%), and STRs
(0.5%). Eleven of the variations are indels and inversions
1100 bp in size; the largest, a 9.7-kb indel halfway be-
tween HLA-B and HLA-C. The mean density of 16.1
SNPs per kb observed for the sequenced region is much
higher than the mean density of 2.9 SNPs per kb seen for
the entire human genome (build 124 of dbSNP).
Analysis of Candidate Genes
In all, 5,545 polymorphisms were found in the 297.8-
kb candidate interval, 205 of them within spliced gene
transcripts. We considered a candidate for PSORS1 to
be either an allele at a single polymorphism or a com-
bination of alleles at multiple polymorphisms that is
unique to risk; that is, present on both risk chromosomes
but absent on all five nonrisk chromosomes. Of the
5,545 polymorphisms, 98 (1.8%) met this criterion when
considered individually. Three of these are SNPs in the
second exon of HLA-C. None of the other 95 polymor-
phisms unique to risk haplotypes occur within spliced
gene transcripts. However, 49 of the 95 occur within
SEEK1 introns, and 2 of these 49 also occur in the first
intron of CDSN, because of the overlapping nature of
these two genes. The distribution of unique individual
SNPs within the PSORS1 candidate region is depicted
in figure 3.
Given the fact that alleles for HLA and non-HLA genes
within the MHC differ by varying combinations of SNPs
and indels, it is important to consider the possibility that
the PSORS1-disease allele differs from other nonrisk al-
leles only when multiple polymorphisms within a func-
tional unit are considered in combination. On the basis
of our sequence data, thousands of two-way and millions
of three-way combinations of polymorphisms within the
candidate interval are unique to risk. Therefore, our
analysis focused on variations found in spliced tran-
scripts of all known genes in the area, with a particular
focus on variations leading to alteration of amino acid
sequences. A summary of the genetic variations, for each
candidate gene, that are unique to risk haplotypes HLA-
Cw6-B57 and HLA-Cw6-B50 is given in table 9. In the
detailed analysis below, gene polymorphisms are named
per the recommendations of Antonarakis et al.,43 with
use of the mRNA reference sequences in table 5.
Seven genes in the candidate interval (HCG27,
PSORS1C3, OTF3, TCF19, HCR, STG, and HCG22)
encode a spliced transcript on one or more psoriasis-
associated haplotypes that is identical in sequence to the
spliced transcripts of one or more nonrisk haplotypes,
which renders each gene a noncandidate for PSORS1 at
the level of mRNA and protein. A further two genes in
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Figure 2 Divergence of sequenced haplotypes from the HLA-Cw6-B57 risk haplotype. Known genes and their direction of transcription
are shown below the coordinate axis, and microsatellite markers are shown above. The 298-kb PSORS1 candidate region is also depicted. The
weighted percentage difference of polymorphism alleles, when compared with the sequence of the HLA-Cw6-B57 haplotype, is plotted by 2.5-
kb intervals for each of the remaining six distinct haplotype clusters that were sequenced. Only those polymorphisms observed among the 10
sequenced haplotypes were considered when computing percentage difference. A plot for the second risk haplotype is shown first, followed
by plots for the five nonrisk haplotypes. The bottom panel plots the number of polymorphisms observed among the 10 sequenced haplotypes,
for 2.5-kb intervals of the sequenced region. The Cw6-B57 haplotype was derived from two individuals, because the region telomeric of
CDSN on the Cw6-B57 chromosome of the person originally selected for cloning is actually derived from a Cw7-B8 haplotype by ancestral
recombination.
the candidate interval (SEEK1 and SPR1) have no pro-
tein alleles specific to risk haplotypes but do have
mRNA sequences that are unique to risk. For SPR1, four
different pairwise combinations of mRNA alleles are
unique to risk and involve five variations: 5′ UTR SNPs
284ArG and 90TrC, missense SNP 248CrT, and
3′ UTR SNPs 506ArG and 673CrG. The four com-
binations specific to the risk haplotypes all involve the
673G allele with 284G, 90C, 248C, or 506A as the
second allele. For the larger of the two known splice
variants of SEEK1, one pairwise combination and four
four-way combinations of mRNA alleles are unique to
risk. Seven polymorphisms are involved in these com-
binations: 5′ UTR variations 199ArG, 100CrT,
94GrA; missense variations 70CrA and 100ArG;
frameshift variation 117delC; and 3′ UTR variation
483TrC. The combinations of polymorphism alleles
unique to risk are (1) 100C and 94A; (2) 199A,
100C, 70C, and 100G; (3) 199A, 100C, 70C, and
483C; (4) 199A, 100C, 100G, and 117 undeleted;
and (5) 199A, 100C, 117 undeleted, and 483C.
Only two genes in the PSORS1 candidate interval
(HLA-C and CDSN) have protein alleles unique to the
two risk haplotypes among the 10 sequenced haplotypes.
For HLA-C, three polymorphisms—silent SNP 213GrC
and missense SNPs 302GrA and 312CrA—each have
an allele (C, A, and A, respectively) that is unique to
the spliced risk transcripts among the 10 sequenced hap-
lotypes. The two unique missense SNPs code for 77Asn
and 80Lys in the HLA-Cw0602 protein of the risk hap-
lotypes, as opposed to 77Ser and 80Asn in the nonrisk
haplotypes. However, these variations are not unique to
www.ajhg.org The American Journal of Human Genetics Volume 78 May 2006 837
Figure 3 Locations of polymorphisms unique to risk haplotypes within the PSORS1 candidate region. Polymorphisms with alleles borne
by the two sequenced risk haplotypes that differ from the alleles borne by all eight sequenced nonrisk haplotypes are plotted, with circles, to
the nearest 5-kb interval. Fill color of the circle indicates whether the polymorphism occurs within a gene exon (red), gene intron (yellow), or
intergenic region (green). Known genes and their direction of transcription and the PSORS1 candidate interval are shown below the coordinate
axis.
HLA-Cw6 transcripts or proteins, either singly or in
combination, among all HLA-C alleles in the most recent
release (2.10.0, July 2005) of the IMGT/HLA Sequence
Database.20 Two pairs of SNP alleles (213C and 361T
and 341A and 361T) are the smallest combinations that
distinguish the spliced transcripts of all 12 known HLA-
Cw6 alleles from those of all 186 known non–HLA-
Cw6 alleles. To specifically distinguish the transcript of
HLA-Cw*0602 (the allele found on the four major risk
haplotypes of this study) from transcripts of all other
HLA-C alleles, including the rare Cw*0603-Cw*0613
alleles, one of nine different nine-way combinations of
SNP alleles is required. A pair of amino acids, 90Asp in
exon 2 paired with a 97Trp in exon 3 (corresponding to
the 341A and 361T allele pair mentioned above), is the
smallest combination that distinguishes all HLA-Cw6
protein alleles from all non–HLA-Cw6 protein alleles.
Four different nine-way combinations of amino acids
uniquely define the Cw*0602 protein among all HLA-
C alleles.
Five different combinations of protein-altering varia-
tions distinguish the CDSN protein of the two sequenced
risk haplotypes from the nonrisk haplotypes. Seven poly-
morphisms are involved in these combinations—mis-
sense SNPs 52ArT, 428GrA, 605CrT, 1222TrG,
1229CrT, and 1579GrA, as well as coding indel 447–
449delAAG. The five allele combinations unique to the
two risk haplotypes are (1) 605T, 1222T, and 1229C;
(2) 428G, 447–449 undeleted, 605T, and 1222T; (3)
52A, 428G, 605T, and 1222T; (4) 447–449 undeleted,
605T, 1222T, and 1579G; and (5) 52A, 605T, 1222T,
and 1579G. The smallest combination unique to the
CDSN gene carried by the risk haplotypes (605T, 1222T,
and 1229C) corresponds to residues 202Phe, 408Ser, and
410Ser in the predicted protein of these haplotypes. These
conclusions are unaffected by the presence of two known
variations in the CDSN protein among risk haplotypes;
the HLA-Cw6-B50 haplotype has a T rather than a C
at missense variation 166CrT (which results in a Phe
rather than Leu at residue 56), and the HLA-Cw6-B13
haplotype has a G rather than an A at missense variation
1201ArG (which results in a Gly instead of Ser at res-
idue 401).44
Association of Psoriasis with HLA-C and CDSN
After we determined that HLA-C and CDSN were the
only genes of the candidate interval encoding protein
alleles unique to risk, we proceeded to type our entire
sample for the seven coding SNPs that uniquely define
HLA-Cw6 and the eight SNPs and one indel that dis-
tinguish the known risk alleles of the CDSN gene. Hap-
lotypes were constructed for each gene as described in
the “Subjects and Methods” section. As shown in ta-
ble 10, HLA-C yielded 9 haplotype alleles, and CDSN
yielded 12 haplotype alleles, 4 of which are rare and not
described elsewhere. The alleles of each gene were then
tested for association with psoriasis by use of the TDT
and the FBAT.
As shown in table 10, only HLA-Cw6 (HLA-C hap-
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Table 9
Polymorphisms in Spliced Transcripts of Known Genes of the PSORS1 Candidate Interval
TYPE OF MRNA POLYMORPHISM OR POLYMORPHISM COMBINATION
NO. OF QUALIFYING POLYMORPHISMS OR POLYMORPHISM COMBINATIONS ATa
HLA-C HCG27 PSORS1C3 OTF3 TCF19 HCR SPR1 CDSN SEEK1 STG HCG22
Missense, nonsense, or coding indel 48 1 0 1 2 8 2 8 3 5 4
Silent 16 1 0 4 2 6 0 10 0 3 2
Noncoding (UTR) 24 8 8 2 2 2 6 6 5 2 14
Total 88 10 8 7 6 16 8 24 8 10 20
Single mRNA polymorphism of any type unique to risk 3 0 0 0 0 0 0 0 0 0 0
Combination of protein-altering mRNA polymorphisms unique to risk 68 0 0 0 0 0 0 5 0 0 0
Combination of mRNA polymorphisms, of any type, unique to risk 6,065 0 0 0 0 0 4 47 5 0 0
a For genes with more than one known splice variant, the maximum number of qualifying polymorphisms or combinations among all variants is reported.
lotype 11) and three of the CDSN haplotypes (1, 3, and
7) are positively associated with psoriasis. For CDSN,
three of the five combinations of polymorphisms that
distinguish the two sequenced risk haplotypes also dis-
tinguish the three associated CDSN haplotypes from all
unassociated haplotypes for the entire pedigree sample.
The other two combinations (52A, 428G, 605T, and
1222T and 52A, 605T, 1222T, and 1579G) are also
carried by CDSN haplotype 8, which appears to be un-
associated with psoriasis. The three CDSN risk haplo-
types differed from each other at missense variations
166CrT and 1201ArG and exhibited somewhat dif-
ferent magnitudes for LD, as measured by the percent-
age transmission values in the TDT (66.2, 67.6, and 72.1
for alleles 1, 3, and 7, respectively; permutation tests
for differences in %T were not significant) or the mod-
ified S statistic in the FBAT (.237, .281, and 336). Be-
cause these three CDSN haplotypes appear to carry sim-
ilar risk for psoriasis, we combined them into one risk
haplotype for subsequent analysis, which we designate
“CDSN*TTC,” because the smallest allele combination
unique to all three risk haplotypes is T, T, and C at
mRNA positions 605, 1222, and 1229.
The association of HLA-Cw6 and CDSN*TTC with
psoriasis is highly significant with use of both tests (table
10). HLA-Cw6 seems to be more strongly associated than
CDSN*TTC (75.3% vs. 72.1% transmission; 3.8#
vs. FBAT P value). However, the dif-25 2310 5.9# 10
ference in TDT T:NT (transmitted:nontransmitted) ra-
tios for the two risk alleles (295:97 vs. 289:112) is not
significant with use of the t test for equality of two pro-
portions ( ).Pp .31
Several of the more common alleles of each gene are
negatively associated with psoriasis. However, these neg-
ative associations are not unexpected, since neutral al-
leles will be noticeably undertransmitted whenever one
or more risk alleles are common and strongly overtrans-
mitted. Consonant with this expectation, T:NT ratios
for the subset of pedigrees lacking the common risk al-
leles show no significantly undertransmitted alleles (data
not shown).
Haplotype-Cluster Analysis
We extended our earlier 34-marker haplotype-clus-
tering analysis14 to include the HLA-C and CDSN genes
and 130 additional pedigrees. We also incorporated im-
proved methods for haplotype reconstruction. In gen-
eral, the results of the new clustering analysis were very
similar to those of the original study, but the larger sam-
ple size yielded more haplotype clusters (76 vs. 66) and
substantially greater power of association tests. Sequenc-
ing the candidate interval greatly improved our ability
to accurately determine regions that were identical by
descent on the basis of microsatellite marker alleles.
Consensus alleles and TDT results for all 36-marker hap-
lotype clusters with a frequency of1% among founder
chromosomes are presented in table 11. Data for all 76
haplotype clusters, including correspondence of old and
new cluster numbers, can be found on the University of
Michigan Psoriasis Genetics Laboratory Web site.
The four identifiable risk haplotypes (defined as “pos-
itive association with psoriasis, with nominal TDT P !
”) share a 300-kb region of homologous marker al-.05
leles between HLA-B and M6S224 that is identical to
the PSORS1 candidate interval identified by sequencing
(fig. 2) and reassessment of our earlier clustering study
(fig. 1). It is likely that the risk haplotypes are derived
from extended ancestral MHC haplotype 57.1 (HLA-
A1-Cw6-B57-DR7-DQ916), represented in its fullest ex-
tent by cluster 44, and the 300-kb candidate interval is
the minimum fragment of this ancestral haplotype re-
tained by all four.
None of the other 11 common haplotype clusters ap-
pear to impart risk for psoriasis, although cluster 51
(designated “cluster 17” in our earlier study14) is over-
transmitted (26:13; 65%) and nearly attains nominal
significance (TDT ). However, the HLA-Cw8-Pp .053
B65 haplotype of cluster 51 was clearly unassociated with
psoriasis in a larger collaborative study17 and in a Sar-
dinian population.46 Haplotype clusters 37 (Cw7-B7), 11
(Cw5-44), and 57 (Cw3-B60) are all significantly under-
transmitted. These same haplotypes remain undertrans-
mitted in the subset of pedigrees lacking all four risk hap-
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lotypes, but their negative association with psoriasis is no
longer significant (data not shown). Whether these hap-
lotypes are truly protective can be determined only by
a larger sample with greater power.
The two prime candidates for the PSORS1 risk allele,
HLA-Cw6 and CDSN*TTC, are both present on all four
risk haplotypes and are both absent from all 11 nonrisk
haplotypes. Hence, the common haplotype clusters pro-
vide no ability to discriminate between these two can-
didates. Risk haplotype clusters do vary in constituent
CDSN alleles and apparent strength of association with
psoriasis. The most common risk haplotype, cluster 44
(HLA-Cw6-B57), which carries the allele 7 variant of
CDSN*TTC, shows the strongest association (78.4%
transmission). The other three risk haplotypes, cluster 47
(Cw6-B13), 43 (Cw6-B37), and 41 (Cw6-B50)—which
carry CDSN*TTC allele variants 1, 7, and 3, respec-
tively—show somewhat weaker associations (69.4%,
70.0%, and 71.4% transmission, respectively), but the
difference in T:NT ratios is not statistically significant.
Analysis of Recombinants between HLA-C and CDSN
Determining whether HLA-C or CDSN is the better
PSORS1 candidate requires identifying and testing an-
cestral recombinants that have separated the risk alleles
of these two genes. To this end, inspection of all 36-
marker haplotypes in 620 families, along with all HLA-
C–CDSN haplotypes in 58 additional families, revealed
76 such recombinant haplotypes among the 684 founder
chromosomes carrying either risk allele. Recombinants
retaining CDSN*TTC (60 in 55 families; 2.1% haplo-
type frequency) were nearly four times as common as
recombinants retaining HLA-Cw6 (16 in 16 families;
0.56% haplotype frequency). Breakpoints for these re-
combinant haplotypes were conservatively mapped, as
described in the “Subjects and Methods” section. Break-
points are not distributed evenly within the 147-kb in-
terval between the two genes. There appears to be a
recombination hotspot just centromeric of CDSN, be-
cause nearly half (36 of 76) of the breakpoints mapped
to the 23-kb interval between M6S198 and CDSN and
nearly 90% (68 of 76) mapped to the 60-kb interval
between M6S169 and CDSN. The variety of breakpoint
locations meant that most recombinant haplotypes were
rare, and only 7 of the 74 recombinant haplotypes were
assigned to a cluster representing greater than five foun-
der chromosomes.
As shown in table 12, association testing of the ances-
tral recombinants excluded CDSN as the PSORS1 gene
with high confidence. Recombinant haplotypes retaining
HLA-Cw6 but lacking CDSN*TTC were positively as-
sociated with psoriasis ( ; PDTT:NTp 11:2 P p .014c
[where Pc is the P value corrected for multiple testing]),
whereas recombinants retaining CDSN*TTC but lacking
HLA-Cw6 were unassociated ( ; TDTT:NTp 15:26
), despite good statistical power (corrected TDTP p .33c
). As depicted in figure 4, grouping re-powerp 98.3%
combinants with similar breakpoints allowed us to test
whether different overlapping portions of the 300-kb can-
didate interval carry PSORS1. HLA-Cw6–positive re-
combinants lacking the M6S190–M6S224 portion of the
candidate interval are still positively associated with pso-
riasis (PDT ), and CDSN*TTC–positive recom-P p .029c
binants carrying the M6S190–CDSN portion of the in-
terval are still unassociated (TDT ; correctedP p .52c
TDT ), which allowed us to exclude thepowerp 98.0%
74.8-kb segment from M6S190 to M6S224 from further
consideration. Even though we do not have power to
confidently exclude more than the telomeric quarter of
the candidate interval, note the consistent lack of asso-
ciation for all seven groups of HLA-Cw6–negative re-
combinants (transmission ! 39%; ) and the
—
D ! 0.21
consistent positive association for all three groups of
HLA-Cw6–positive recombinants (transmission 1 84%;
). If these trends of association are confirmed
—
D 1 0.64
in a larger sample, we should be able to exclude the
entire 129-kb gene-rich region spanning PSORS1C3 and
M6S224 from the candidate interval.
One group of recombinants, represented by the last
line of table 12, is equivalent to the HLA-Cw7-B58
recombinant found to be positively associated with pso-
riasis in both a family and case-control sample of Sar-
dinian psoriatics.46 Although this haplotype appears to
be unassociated in our families ( , TDTT:NTp 4:7
), our sample has only 36% power to detect anP p .94c
association. We fine mapped the recombination break-
points of this haplotype with 15 additional markers. As
shown in figure 5, if the results of both studies are cor-
rect, then PSORS1 would lie within the 38 kb of overlap
between that portion of the HLA-Cw7-B58 haplotype
derived from the ancestral 57.1 haplotype and our re-
duced 224-kb candidate interval. Only two genes in this
overlap region (SPR1 and SEEK1) have spliced transcript
alleles unique to the sequenced risk haplotypes; however,
both genes lie in the segment from M6S198 to CDSN
that can be excluded with good confidence, by the TDT,
from the candidate interval (79% corrected power) (ta-
ble 12).
Analysis of Rare HLA-Cw6 Haplotypes
On the basis of the preceding analyses, HLA-Cw6 is
the best candidate for PSORS1. If HLA-Cw6 is indeed
the PSORS1 risk allele, then any haplotype carrying it
should bear risk. As already seen, this certainly appears
true for the four most common HLA-Cw6 haplotype
clusters (table 11) and for the rare HLA-Cw6/CDSN*
TTC recombinants (table 12). Three relatively uncom-
mon 36-marker haplotype clusters (40, 45, and 46) also
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Figure 4 Recombinant haplotypes and test regions used to map the PSORS1 locus. Key genes and their direction of transcription, along
with microsatellite markers used in this study, are depicted immediately above the coordinate axis. All founder haplotypes bearing an ancestral
recombination between the HLA-Cw6 and CDSN*TTC psoriasis risk alleles are shown above the axis, and those regions tested for exclusion
of the PSORS1 locus are shown below the axis. Haplotypes and test regions of the unassociated (see table 12) HLA-Cw6/CDSN*TTC
recombinants are shown in red; those of the associated HLA-Cw6/CDSN*TTC recombinants are shown in blue. Line segments for the
recombinant haplotypes indicate that portion of the extended HLA-Cw6/CDSN*TTC risk haplotype within the 298-kb PSORS1 candidate
region that is retained by the recombinant; to be conservative, the largest possible portion of the extended risk haplotype carried by HLA-
Cw6 recombinants and the smallest possible portion of the extended haplotype not carried by HLA-Cw6 recombinants are plotted. The test
regions and their bounds are shown in the same order as in table 12. The numbers of founder chromosomes in the pedigree sample are shown
for each recombinant haplotype, as are the numbers of qualifying recombinant founder chromosomes for each of the tests for exclusion.
carry HLA-Cw6 (table 11). All three are overtransmitted
to affected children, but power is too low to achieve a
statistically significant association, because these clus-
ters have haplotype frequencies !0.5% (table 11). Com-
bining all HLA-Cw6–positive haplotypes outside of the
four common risk clusters into a single group (frequency
2.9%) increases power and yields a significant associa-
tion ( ; TDT ; PDT ).T:NTp 36:19 Pp .030 Pp .018
Although the four common risk clusters combined yield
a higher percentage transmission than do other HLA-
Cw6 haplotypes (76.0% vs. 65.5%), this difference is
not significant ( ), and the disparity in strengthPp .34
of LD is not much greater than what is predicted (74.7%
vs. 70.8%) by simulation under the null hypothesis that
they have identical effects and differ only in frequency.
Another test of the hypothesis that HLA-Cw6 is the
disease allele is the comparison of the strength of asso-
ciation for two different kinds of HLA-Cw6 haplo-
types—those that perfectly match the consensus risk al-
leles of microsatellite markers in the reduced 224-kb
candidate interval and those that have at least one allele
mismatch for these markers. For this analysis, only those
12 markers for which the risk allele is found on at least
99% of the haplotypes in the four common risk clusters
were used (i.e., M6S101, M6S167, M6S111, and M6S169
were excluded). Perfect-match haplotypes were abundant
(19.4% haplotype frequency) and strongly associated
with psoriasis (264:87; TDT ), whereas22Pp 7.3# 10
mismatch haplotypes were much less frequent (1.8%)
but still positively associated (22:10; TDT ;Pp .050
PDT ). The difference in transmission ratiosPp .014
(75.2% vs. 68.8%) is not significant ( ). To re-Pp .81
duce the possibility that mismatches with the consensus
risk-haplotype signature were simply the result of typing
or phasing errors, we also tested the association of all
HLA-Cw6 haplotypes with at least two mismatches for
the 12 conserved markers of the candidate interval. This
group of haplotypes shows strong LD with psoriasis (10:
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Figure 5 Comparison of the reduced PSORS1 candidate region, established by this study, with two rare haplotypes that are possibly
associated with psoriasis. Above the coordinate axis, the I-shaped line segment depicts the boundaries of the 224-kb reduced PSORS1 candidate
interval, and unblackened rectangles depict the maximum possible regions of the “double recombinant” HLA-Cw6-B45 (cluster 40) and HLA-
Cw7-B58 putative risk haplotypes that are homologous to the ancestral HLA-Cw6-B57 risk haplotype. Known genes and their direction of
transcription are depicted below the axis. A summary of the psoriasis-risk status of these two haplotypes, as determined by this study and other
studies, is also shown.
3; 76.9% ), but the association is no longer
—
Dp 0.464
significant (TDT ; PDT ) because ofPp .092 Pp .083
the reduction in sample size. In summary, the study of
our families suggests that the PSORS1 risk allele is pre-
sent on all HLA-Cw6 haplotypes.
The most common of the minor HLA-Cw6 haplotype
clusters, cluster 40, is an HLA-Cw6-B45 haplotype that
appears to have originated as a double recombinant of
the 57.1 ancestral haplotype. Fine mapping of its break-
points shows that it retains the centromeric and telo-
meric ends of the candidate interval, including the HLA-
Cw6 and CDSN*TTC risk alleles, but it lacks the risk
haplotype sequence for the intervening segment that in-
cludes PSORS1C3, OTF3, TCF19, HCR, SPR1, and part
of SEEK1 (fig. 5). In our families, this haplotype appears
to be associated with psoriasis ( and
—
T:NTp 7:2 Dp
when cluster 40 is extended to include all hap-0.533
lotypes matching its consensus alleles within the 300-kb
candidate interval), but we have no power to demon-
strate significant association. This same haplotype, also
known as “cluster D,” has been demonstrated to be over-
transmitted to affected children in a study of European
families15 and to be significantly associated with psori-
asis in a case-control study of Gujarati Indians.47 If the
HLA-Cw6-B45 haplotype does indeed bear PSORS1,
then, in conjunction with our results, the candidate in-
terval is further reduced to the 158-kb segment between
HLA-B and PSORS1C3, which excludes all known genes
except HLA-C and HCG27.
If HLA-C is indeed the PSORS1 gene, then, in the
absence of allelic heterogeneity, no haplotype lacking
HLA-Cw6 should be associated with psoriasis. This is
exactly what is observed for haplotypes common enough
to provide adequate power for association testing (table
11), even when excluding all families bearing any HLA-
Cw6 haplotypes (data not shown).
Discussion
We used a combination of genomic DNA sequencing
and haplotype analysis in an effort to complete the ge-
netic dissection of PSORS1. Our principal findings are:
(1) haplotypes that belong to the same cluster are ex-
tremely similar; (2) the PSORS1 gene must reside in
a 297.8-kb interval defined by a region of unbroken
sequence homology between the HLA-B57-Cw6 and
HLA-B50-Cw6 haplotypes; (3) only 98 of 5,545 poly-
morphisms in this interval have alleles specific to risk
haplotypes, but many combinations of alleles at the re-
maining polymorphisms can specifically tag the risk hap-
lotype; (4) HLA-C and CDSN are the only genes in the
candidate interval that encode protein variations unique
to risk among the 10 sequenced haplotypes; (5) analysis
of recombinants mapping between HLA-C and CDSN
implicates HLA-Cw6 rather than CDSN*TTC as the
likely disease allele, and further analysis of these recom-
binants allows us to exclude the telomeric quarter of the
297.8-kb risk interval with high confidence; and (6) in
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our families, all HLA-Cw6 haplotypes and only HLA-
Cw6 haplotypes appear to carry risk for psoriasis.
To our knowledge, our study is the most extensive
resequencing of the MHC class I region reported to date.
We uncovered remarkable variation in nucleotide diver-
sity among different haplotypes across the proximal
class I region, particularly in the vicinity of HLA-B and
HLA-C (fig. 2). Our results confirm and extend previous
findings of high nucleotide diversity in this region.24,48
In contrast to sequences drawn from different haplotype
clusters, sequences drawn from the same haplotype clus-
ter are extremely similar (table 8), which increases con-
fidence that a single sequence can adequately represent
the entire cluster.
We defined a 297.8-kb risk interval on the basis of
extended sequence similarity between the HLA-Cw6-B57
and HLA-Cw6-B50 risk haplotypes (fig. 2). That these
haplotypes should resemble each other over such a long
interval is not surprising, since they are clearly derived
from a common ancestor who carried the risk deter-
minant on extended MHC haplotype 57.1. However, the
divergence between them in the risk interval (0.25 var-
iations per kb) is much greater than the divergence of
any two sequences drawn from the same haplotype clus-
ter (0.0088–0.034 variations per kb) (table 8), which
suggests that the PSORS1 determinant is relatively old.
We identified extensive stretches of low nucleotide di-
vergence between the risk haplotypes and the nonrisk
haplotypes HLA-Cw7-B8, HLA-Cw8-B65, and HLA-
Cw12-B38 (fig. 2), in agreement with analysis of mi-
crosatellite haplotype clusters14 (table 11). Indeed, the
similarity between HLA-Cw8-B65 and HLA-Cw6 risk
haplotypes falsely reinforced our confidence that this
haplotype was risk conferring.14 In retrospect, it is ap-
parent that recurrence of long haplotype stretches is not
a rare event. The long stretches of homologous haplo-
types among sequenced chromosomes probably reflect
the combined effects of natural selection on the MHC
and a relatively low meiotic recombination rate across
this region.12 Our haplotype analysis found a recombi-
nation fraction of for a 1.2-Mb interval en-vp 0.004
compassing the proximal half of the MHC class I region,
which is one-third the predicted genomewide rate.
Regions of sequence similarity between risk and non-
risk haplotypes allowed us to eliminate most individual
sequence variants as PSORS1 candidates. Sequencing of
other common nonrisk haplotypes (e.g., clusters 11, 68,
22, 57, 29, and 5 in table 11) could allow further re-
duction of the number of variants unique to risk hap-
lotypes. However, the number of unique combinations
of polymorphisms would still be enormous, which is why
we restricted our combinatorial analysis to spliced tran-
scripts of known genes as the most likely candidates.
As summarized in table 9, our analysis of PSORS1
candidate genes is the most comprehensive to date. We
found that 7 of the 11 known genes in the risk interval—
HCG27, PSORS1C3, OTF3, TCF19, HCR, STG, and
HCG22—are unlikely candidates because, for each gene,
the spliced transcript of at least one common nonrisk
haplotype is identical in sequence to that of the risk
haplotypes. We are the first to study the association of
HCG22 and HCG27 with psoriasis. Others have found
TCF19 and STG to be unassociated,49,50 and PSORS1C3
was found to be more weakly associated with psoriasis
than was HLA-Cw*0602.51 The WWCC protein allele
of HCR has been reported to be strongly associated with
psoriasis,52–54 and HCR is expressed differently in pso-
riatic skin55 and in transgenic mice carrying the HCR*
WWCC risk allele.56 However, none of these studies
could differentiate the genetic association of HCR*
WWCC with disease from that of HLA-Cw6, which are
carried together on nearly all risk haplotypes in the sam-
pled populations. Indeed, we57 and others58 found the
association of HCR to be weaker than that of HLA-C,
as would be predicted by our current sequence analysis.
Although one study found OTF3 to be unassociated
with psoriasis in a Chinese population,59 another study
found that an allele of a HindIII polymorphism in OTF3
was more strongly associated with psoriasis in a Spanish
population than was HLA-Cw*0602 itself.60 Our data
definitely do not support this OTF3 allele as a PSORS1
candidate, because the HindIII risk allele (1321T) is
found on both splice variants of at least three common
nonrisk haplotypes. Furthermore, its location in the 3′
UTR of the gene lessens the likelihood that it has func-
tional consequences.
SPR1 and SEEK1 have mRNA alleles unique to risk
among the 10 haplotypes we sequenced, but these do
not affect protein sequence, so there are no protein al-
leles for these genes unique to risk haplotypes. SPR1
was found to be associated with psoriasis in two other
studies.61,62 The first study reported significant associa-
tions for two mRNA haplotypes carrying the same four
pairwise combinations of alleles that we find to be
unique to risk; the second study detected association
even though analysis was restricted to single SNPs, none
of which included the critical 3′ UTR 673GrC SNP com-
mon to all combinations that uniquely tag the risk hap-
lotype in our analysis. Neither study could demonstrate
an SPR1 association independent of association with
HLA-Cw6. Conflicting results have been reported for
SEEK1. A study of Chinese psoriatics63 could find no
association with SEEK1 polymorphisms, considered ei-
ther individually or as haplotypes, but a study of Swedish
psoriatics62 did find a HLA-Cw*0602–independent as-
sociation with two SNP alleles (94A and 100C) that
constitute one of the combinations we found to be
unique among our sequenced haplotypes. However, the
P values for HLA-Cw*0602–independent association of
SEEK1 obtained in that study would not have been sig-
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nificant if corrected for multiple testing, and the positive
association reported for SNP 100C in that study is
actually for the allele not carried on HLA-Cw6 haplo-
types and hence does not comprise the combination that
we found to be unique to risk. Among our sequenced
haplotypes, this allele is found only on those carrying
HLA-Cw*1203, which are definitely nonrisk in our fam-
ilies. Moreover, these two SEEK1 polymorphisms lie
outside the 224-kb reduced risk interval determined by
recombinant haplotype mapping (fig. 5). On the basis
of these considerations, we conclude that variation at
SEEK1 does not adequately explain the risk of psoriasis
conferred by PSORS1.
HLA-C and CDSN are the only candidates with pre-
dicted protein alleles unique to risk among the 10 se-
quenced haplotypes. We genotyped our full family sam-
ple for the risk alleles of these two genes that were
identified by our sequence analysis and other studies. Of
the 15 groups of HLA-C alleles distinguishable by our
typing assay (table 10), 9 occur in our families, and only
HLA-Cw6 is positively associated with psoriasis. Of the
12 alleles typed for CDSN, 3 are positively associated.
Because we could not demonstrate significant differences
in the degree of risk conferred by the three alleles, we
lumped them into a single risk allele, CDSN*TTC,
named for the smallest combination of polymorphism
alleles distinguishing it from nonrisk variants. Associa-
tion for both HLA-Cw6 and CDSN*TTC is very strong
(172% transmission; PDT ) and highly signif-
—
D 1 0.48
icant (FBAT ) (table 10).23P ! 6# 10
CDSN is an excellent functional candidate for PSORS1,
since it is a secreted protein that mediates homophilic
adhesion between terminally differentiated keratinocy-
tes. Its degradation by serine proteases results in their
desquamation from the stratum corneum.64 Psoriasis is
characterized by a markedly defective stratum corneum,
with immature corneocytes and large increases in tran-
sepidermal water loss.65 Moreover, CDSN is expressed
and secreted into the extracellular space in the upper
spinous layers of lesional psoriatic skin, whereas this
does not occur until keratinocytes reach the granular
layer in normal and nonlesional psoriatic skin.66 Many
groups have studied the association of CDSN with pso-
riasis. Several groups—three from Japan67–69 and one
each from Spain,60 China,59 and Finland52—could find
no association between CDSN and psoriasis. These neg-
ative studies, however, all suffer from one or more fac-
tors that reduced their power to detect association, in-
cluding small sample size, lack of haplotyping, and
incomplete description of allelic variation. In contrast,
many other studies have detected positive association of
psoriasis and CDSN. Many of these studies offer no
compelling evidence that differentiates the association of
psoriasis with CDSN from its association with risk al-
leles of other genes in strong LD with CDSN, especially
HLA-Cw6 and HCR*WWCC.44,53,68–71 Others present
evidence that the observed association between CDSN
and psoriasis is at least partially independent of that seen
for HLA-C.46,72–76 Yet others argue that both HLA-C and
CDSN are necessary for disease.15,47 Finally, a recently
published study77 localized PSORS1 to a haplotype block
containing HLA-C but not HCR or CDSN.
In light of the conflicting evidence for the role of
CDSN versus HLA-C in psoriasis, we designed a study
that addresses many of the shortcomings of previous
work. We recruited a sample larger than any published
to date and used families rather than cases and controls,
to guard against spurious associations and to allow for
more accurate haplotype reconstruction. We required that
the proband of each family have early-onset (type I)
psoriasis, which increases the probability of MHC in-
volvement.10 We rigorously typed HLA-C, using a novel
approach that distinguishes HLA-Cw6 alleles from all
other 186 known alleles of the gene, even in the absence
of external phase information from a family or popu-
lation. In addition to the three SNPs constituting the
CDSN*TTC variant, we typed CDSN for four other
protein-altering polymorphisms involved in combina-
tions distinguishing the CDSN of risk haplotypes among
our 10 sequenced chromosomes, as well as for two var-
iants causing CDSN protein changes among different
HLA-Cw6–bearing haplotypes. Finally, we haplotyped
CDSN and HLA-C with 14 intervening and 20 flanking
microsatellite markers, greatly reducing the chances of
identifying false recombinants that are simply the result
of typing or phasing errors.
Our single-gene association analysis favors HLA-Cw6
over CDSN*TTC because of its somewhat higher levels
of LD with psoriasis (table 10), but the difference is not
statistically significant. Among haplotype clusters com-
mon enough to have power for association testing, the
four that are positively associated with psoriasis carry
the risk alleles for both genes (table 11). We then iden-
tified recombinants between the two risk alleles, which
are infrequent (2.6% haplotype frequency) in our fam-
ilies and hence require a large sample for meaningful
analysis. Using simulation methods to establish an ap-
propriate correction for multiple testing, we are able to
exclude CDSN*TTC as the PSORS1 risk allele with high
confidence (table 12). By grouping haplotypes on the
basis of their breakpoints, we are also able to exclude
the telomeric 25% of the risk interval, extending from
M6S190 to M6S224 (fig. 5).
We restricted our analysis of candidate genes to those
known to be translated or transcribed. The original 300-
kb candidate interval also contains four pseudogenes
(WASF5P, RPL32P, USP8P, and POLR2LP) and one
computer-predicted locus (LOC442199). Of these, only
WASF5P and USP8P have sequences unique to the risk
among the 10 sequenced haplotypes (data not shown).
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Although both of these pseudogenes map within 20 kb
of HLA-C, their lack of expression makes them poor
candidates for PSORS1. We can also exclude a tran-
scribed fragment of an endogenous retroviral dUTPase
advanced elsewhere as a candidate for PSORS178 (data
not shown).
All demonstrable risk haplotypes in our families carry
HLA-Cw6, and all HLA-Cw6 haplotypes, even the rare
ones when considered in aggregate, appear to impart
risk for psoriasis. Conversely, all demonstrable nonrisk
haplotypes lack HLA-Cw6. The same cannot be said for
any protein allele of any other gene in the candidate
region or for any spliced mRNA allele of any gene other
than SPR1 and SEEK1. Because PSORS1 probably lies
within the 158-kb interval of conserved risk sequence
between HLA-B and PSORS1C3 that is common to our
reduced candidate interval and the HLA-Cw6-B45 risk
haplotype (fig. 5), we can also exclude the risk-associated
mRNA alleles of SPR1 and SEEK1 as candidates. Given
these results, HLA-Cw6 is clearly the best candidate for
PSORS1. Nevertheless, we cannot rule out intronic var-
iations in known genes of the reduced candidate interval
that influence transcription, mRNA processing, or long-
range chromatin structure. We also cannot rule out reg-
ulatory variations flanking known genes or undiscovered
genes or regulatory RNAs in this remaining interval.
Ongoing international collaborative studies involving
thousands of additional subjects should allow these re-
maining questions to be addressed through further de-
tailed analysis of informative recombinants.
Although Orru` et al. identified the HLA-Cw7-B58
haplotype as risk-conferring,46 and this haplotype does
carry a segment homologous to the ancestral HLA-Cw6-
B57 risk haplotype (fig. 5), the few individuals carrying
this haplotype in our sample provide no support for this
conclusion ( ). Moreover, figure 5 demon-T:NTp 4:7
strates that the region of overlap between this haplotype
and the reduced risk interval established by the pres-
ent study is not carried by the HLA-Cw6-B45–bear-
ing “double recombinant” putative risk haplotype also
known as “cluster D.”15,47 Interestingly, an allele of the
MICA gene that is in strong LD with the HLA-Cw7-
B58 haplotype79 has recently been associated with pso-
riatic arthritis.80 Consistent with this finding, 60% (6 of
10) of the evaluable psoriatics in our sample who carried
HLA-Cw7-B58 had joint complaints, as opposed to
28.5% (285 of 1,001) of evaluable psoriatics not car-
rying this haplotype. Orru` et al.46 did not mention how
many of the psoriatics in their sample were affected with
arthritis. Clearly, it will be important to stratify any fu-
ture analysis of this haplotype for the presence or ab-
sence of joint disease.
Our studies do not exclude the possibility that allelic
heterogeneity in psoriasis involves the closely related
HLA-B and HLA-C genes. Indeed, the HLA-Cw1-B46
haplotype, which is essentially specific to East Asian pop-
ulations81 and is not present in our sample, has been
associated with psoriasis in several studies.82–86 Also, in
addition to HLA-Cw6, HLA-B38 and HLA-B39 have
been associated with psoriatic arthritis in multiple stud-
ies.87–91 However, further studies will be required to de-
termine whether these additional disease-associatedHLA-
B and/or HLA-C alleles play causal roles or reflect LD
with a nearby causal gene.
Our genetic findings in support of HLA-Cw6 as a
major disease allele at PSORS1 are congruent with cur-
rent concepts of psoriasis immunopathogenesis. Whereas
the most prominent clinical features of psoriasis are epi-
dermal hyperplasia and increased cutaneous blood flow,
multiple lines of evidence indicate that these changes are
triggered and maintained by infiltrating immunocytes.
Psoriasis has been triggered or cured by bone-marrow
transplantation, depending on whether the donor or the
host was psoriatic, and T cell–specific immunosuppres-
sants such as cyclosporine A and FK506 exert dramatic
therapeutic effects.4,92 Studies of T cell receptor (TCR)
rearrangements have documented the presence of oli-
goclonal T cell expansions in multiple psoriatic lesions
of the same subject, which persist after improvement
followed by relapse (references in the work of Lin et
al.93). These oligoclonal proliferations involve CD8 as
well as CD4 T cells.94 HLA-Cw6 seems well suited for
a role in this process, since HLA-C presents peptide an-
tigens to CD8 T cells, and CD8 T cells comprise at
least 80% of the T cells in lesional psoriatic epidermis.5
HLA-C also regulates the activity of natural killer cells
by interacting with killer immunoglobulinlike receptors
(KIR).95 Interestingly, variation in KIR genes has been
associated with psoriasis96,97 and psoriatic arthritis.98,99
In aggregate, these data strongly suggest that HLA-
Cw6 is the major disease allele at the PSORS1 locus that
confers early-onset disease in white populations. Future
genetic studies of this locus should focus on large col-
laborative collections of subjects so that more critical
recombinants can be identified to further reduce the
PSORS1 candidate interval. The polymorphisms we
have identified here will be very useful for this task. Also,
additional sequenced haplotypes can be applied to can-
didate-locus analysis, further decreasing the number of
polymorphisms and combinations of polymorphisms
unique to risk. Now that the extreme similarity of un-
related examples of the same haplotype has been dem-
onstrated (table 8) and the risk status of most com-
mon HLA-C-B haplotypes is known (table 11), these
sequences no longer need to be cloned in an allele-spe-
cific fashion from psoriasis-affected families as we have
done but can be derived from homozygous HLA typing
cell lines identified on the basis of their HLA-C-B hap-
lotypes.24 Future functional studies of PSORS1 should
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be directed toward elucidating the role of HLA-Cw6 in
the immunopathogenesis of psoriasis.
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